With 1.66 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.55 million shares. The 52-week range on GMED shows that it touched its highest point at $94.93 and its lowest point at $54.48 during that stretch. It currently has a 1-year price target of $85.17. Beta for the stock currently stands at 1.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GMED was up-trending over the past week, with a rise of 1.35%, but this was down by -18.37% over a month. Three-month performance dropped to -27.01% while six-month performance fell -28.39%. The stock lost -11.56% in the past year, while it has lost -29.15% so far this year. A look at the trailing 12-month EPS for GMED yields 1.34 with Next year EPS estimates of 3.73. For the next quarter, that number is 0.79. This implies an EPS growth rate of 1.75% for this year and 16.61% for next year. EPS is expected to grow by 9.94% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -13.26%.
Float and Shares Shorts:
At present, 112.93 million GMED shares are outstanding with a float of 112.16 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GMED since 10 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $3.00831 being high and $2.91806 being low. For GMED, this leads to a yearly average estimate of $2.98825. Based on analyst estimates, the high estimate for the next quarter is $0.86 and the low estimate is $0.74. The average estimate for the next quarter is thus $0.8.
